Retinal ganglion cell neuroprotection in a rat model of glaucoma following brimonidine, latanoprost or combined treatments

Experimental Eye Research

Volumn 86, Issue 5, 2008, Pages 798-806

  Hernández, María ^a   Urcola, J Haritz ^a,b   Vecino, Elena ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b HOSPITAL DE MENDARO   (Spain)

Author keywords

apoptosis; BDNF; brimonidine; glaucoma; glutamate; IOP; latanoprost; neuroprotection; rat

Indexed keywords

BRIMONIDINE; FLUOROGOLD; LATANOPROST;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DENSITY; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; GLAUCOMA; INTRAOCULAR PRESSURE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; RETINA GANGLION CELL;

ANIMALS; ANTIHYPERTENSIVE AGENTS; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; FEMALE; GLAUCOMA, OPEN-ANGLE; INTRAOCULAR PRESSURE; NEUROPROTECTIVE AGENTS; PROSTAGLANDINS F, SYNTHETIC; QUINOXALINES; RATS; RATS, SPRAGUE-DAWLEY; RETINAL GANGLION CELLS;

EID: 42749091665     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exer.2008.02.008     Document Type: Article

References (56)

1. Acheampong A.A., Shackleton M., John B., Burke J., Wheeler L., and Tang-Liu D. Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit, and rat eyes. Drug Metab. Dispos. 30 (2002) 421-429
2. Ahmed F., Hegazi K., Chaudhray P., and Sharma S.C. Neuroprotective effect of α2 agonist (brimonidine) on adult rat retinal ganglion cells after increased intraocular pressure. Brain Res. 913 (2001) 133-139
3. Aihara M., Lindsey J.D., and Weinreb R.N. Reduction of intraocular pressure in mouse eyes treated with latanoprost. Invest. Ophthalmol. Vis. Sci. 43 (2002) 146-150
4. Alm A., Camras C.B., and Watson P.G. Phase 3 latanoprost studies: masked 6-month comparisons with timolol, in the United Kingdom, Scandinavia and USA. Surv. Ophthalmol. 41 (1997) 105-110
5. Altuna J.C., Greenfield D.S., Liebmann J.M., Taglia D.P., Kaufman P.L., Cioffi G.A., Lee D.A., Robin A.L., Crichton A., Costa V.P., and Ritch R. Latanoprost in glaucoma associated with Sturge-Weber syndrome: benefits and side-effects. J. Glaucoma 8 (1999) 199-203
6. Benozzi J., Nahum L.P., Campanelli J.L., and Rosenstein R.E. Effect of hyaluronic acid on intraocular pressure in rats. Invest. Ophthalmol. Vis. Sci. 43 (2002) 2196-2200
7. Bernard L.M., Althin R., Dhawan R., Grima D.T., Lam A., and Aballea S. Clinical and economic impacts of latanoprost 0.005% in first-line treatment of open-angle glaucoma and ocular hypertension in France. Eur. J. Ophthalmol. 13 (2003) 30-43
8. Camras C.B. United States Latanoprost Study Group: comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month, masked, multicenter trial in the United States. Ophthalmology 103 (1996) 138-147
9. Crowston J.G., Aihara M., Lindsey J.D., and Weinreb R.N. Effect of latanoprost on outflow facility in the mouse. Invest. Ophthalmol. Vis. Sci. 45 (2004) 2240-2245
10. Danias J., Shen F., Goldblum D., Chen B., Ramos-Esteban J., Podos S.M., and Mittag T. Cytoarchitecture of the retinal ganglion cells in the rat. Invest. Ophthalmol. Vis. Sci. 43 (2002) 587-594
11. Danias J., Shen F., Kavalarakis M., Chen B., Goldblum D., Lee K., Zamora M.F., Su Y.L., Podos S.M., and Mittag T. Characterization of retinal damage in the episcleral vein cauterization rat glaucoma model. Exp. Eye Res. 82 (2006) 219-228
12. Donello J.E., Padillo E.U., Webster M.L., Wheeler L.A., and Gil D.W. Alpha (2)-adrenoceptor agonists inhibit vitreal glutamate and aspartate accumulation and preserve retinal function after transient ischemia. J. Pharmacol. Exp. Ther. 1 (2001) 216-223
13. Fechter R.D., and Realini T. Fixed combinations of topical glaucoma medications. Curr. Opin. Ophthalmol. 15 (2004) 132-135
14. Gabelt B.T., and Kaufman P.L. Prostaglandin increases uveoscleral outflow in cynomolgus monkey. Exp. Eye Res. 49 (1989) 389-402
15. Gagliuso D.J., Wang R.F., Mittag T.W., and Podos S.M. Additivity of brimatoprost or travatoprost to latanoprost in glaucomatous monkey eyes. Arch. Ophthalmol. 122 (2004) 1342-1347
16. Gao H., Qiao X., Cantor L.B., and WuDun D. Up-regulation of brain-derived neurotrophic factor expression by brimonidine in rat retinal ganglion cells. Arch. Ophthalmol. 120 (2002) 797-803
17. Grunder T., Kohler K., Kaletta K., and Guenther E. The distribution and developmental regulation of NMDA receptor subunit proteins in the outer and inner retina of the rat. J. Neurobiol. 44 (2000) 333-342
18. Heijl A., Leske M.C., Bengtsson B., Hyman L., Bengtsson B., Hussein M., and Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch. Ophthalmol. 120 (2002) 1268-1279
19. Higginbotham E.J., Diestelhorst M., Pfeiffer N., Rouland J.F., and Alm A. The efficacy and safety of unfixed and fixed combinations of latanoprost and other antiglaucoma medications. Surv. Ophthalmol. 47 (2002) S133-S140
20. - and cell volume. J. Neurochem. 71 (1998) 1396-1404
21. Ishii K., and Araie M. Effect of topical latanoprost-timolol combined therapy on retinal blood flow and circulation of optic nerve head tissue in cynomolgus monkey. Jpn. J. Ophthalmol. 44 (2000) 227-234
22. Ishii K., Tomidokoro A., Nagahara M., Tamaki Y., Kanno M., Fukaya Y., and Araie M. Effects of topical latanoprost on optic nerve head circulation in rabbits, monkeys, and humans. Invest. Ophthalmol. Vis. Sci. 42 (2001) 2957-2963
23. Jeng Y.Y., Lin N.T., Chang P.H., Huang Y.P., Pang V.F., Liu C.H., and Lin C.T. Retinal ischemic injury rescued by sodium 4-phenylbutyrate in a rat model. Exp. Eye Res. 84 (2007) 486-492
24. Lafuente M.P., Villegas-Perez M.P., Sobrado-Calvo P., Garcia Aviles A., Miralles de Imperial J., and Vidal-Sanz M. Neuroprotective effects of alpha (2)-selective adrenergic agonists against ischemia-induced retinal ganglion cell death. Invest. Ophthalmol. Vis. Sci. 42 (2001) 2074-2084
25. Lafuente M.P., Villegas-Pérez M.P., Mayo R.S., Aguilera M.E., Miralles de Imperial J., and Vidal-Sanz M. Neuroprotective effects of brimonidine against transient ischemia-induced retinal ganglion cell death: a dose response in vivo study. Exp. Eye Res. 74 (2002) 181-189
26. Lai R.K., Chun T.Y., Hasson D.W., and Wheeler L.A. Activation of cell survival signaling pathway in the retina by selective alpha-2 adrenoceptor agonist brimonidine. Invest. Ophthalmol. Vis. Sci. 40 (1999) S763
27. Lee D.A., and Gornbein J.A. Effectiveness and safety of brimonidine as adjunctive therapy for patients with elevated intraocular pressure in a large, open-label community trial. J. Glaucoma 10 (2001) 220-226
28. Lee D.A., and Higginbotham E.J. Glaucoma and its treatment: a review. Am. J. Health-Syst. Pharm. 62 (2005) 691-699
29. Leske M.C., Heijl A., Hussein M., Bengtsson B., Hyman L., Komaroff E., and for the Early Manifest Glaucoma Trial Group. Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial. Arch. Ophthalmol. 121 (2003) 48-56
30. Li H., Tran V.V., Hu Y., MarkSaltzman W., Barnstable C.J., and Tombran-Tink J. A PEDF N-terminal peptide protects the retina from ischemic injury when delivered in PLGA nanospheres. Exp. Eye Res. 83 (2006) 824-833
31. MacLaren R.E., Buch P.K., Smith A.J., Balaggan K.S., MacNeil A., Taylor J.S., Osborne N.N., and Ali R.R. CNTF gene transfer protects ganglion cells in rat retina undergoing focal injury and branch vessel occlusion. Exp. Eye Res. 83 (2006) 1118-1127
32. Mishima H.K., Kiuchi Y., Takamatsu M., Ratz P., and Bito R.Z. Circadian intraocular pressure management with latanoprost: diurnal and nocturnal intraocular pressure reduction and increased uveoscleral outflow. Surv. Ophthalmol. 41 (1997) S139-S144
33. Nilsson S.F., Samuelsson M., Bill A., and Stjernschantz J. Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F-2-1-isopropylester in cynomolgus monkey. Exp. Eye Res. 48 (1989) 707-716
34. Ota T., Hara H., and Miyawaki N. Brain-derived neurotrophic factor inhibits changes in soma-size of retinal ganglion cells following optic nerve axotomy in rats. J. Ocul. Pharmacol. Ther. 18 (2002) 241-249
35. Pang I.H., Wang W.H., and Clark A.F. Acute effects of glaucoma medications on rat intraocular pressure. Exp. Eye Res. 80 (2005) 207-214
36. Quigley H.A., Engerm C., Katz J., Sommer A., Scottm R., and Gilbertm D. Risk factors for the development of glaucomatous visual field loss in ocular hypertension. Arch. Ophthalmol. 112 (1994) 644-649
37. Reitsamer H.A., Kiel J.W., Harrison J.M., Ransom N.L., and McKinnon S.J. Tonopen measurement of intraocular pressure in mice. Exp. Eye Res. 78 (2004) 799-804
38. Richter M., Krauss A.H., Woodward D.F., and Lütjen-Drecoll E. Morphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prostamide. Invest. Ophthalmol. Vis. Sci. 44 (2003) 4419-4426
39. Ruiz-Ederra J., García M., Hernández M., Urcola H., Hernandez-Barbachano E., Araiz J., and Vecino E. The pig eye as a novel model of glaucoma. Exp. Eye Res. 81 (2005) 561-569
40. Ruiz G., Wheeler L., WoldeMussie E., and Wheeler L.A. Time course of pre or post treatment by brimonidine on neuroprotection in rat optic nerve injury model. Invest. Ophthalmol. Vis. Sci. 41 (2000) S830
41. Schuettauf F., Rejdak R., Thaler S., Bolz S., Lehaci C., Mankowska A., Zarnowski T., Junemann A., Zagorski Z., Zrenner E., and Grieb P. Citicoline and lithium rescue retinal ganglion cells following partial optic nerve crush in the rat. Exp. Eye Res. 83 (2006) 1128-1134
42. Schuman J.S., Horwitz B., Choplin N.T., David R., Albracht D., and Chen K. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension: a controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study group. Arch. Ophthalmol. 115 (1997) 847-852
43. Shareef S.R., Garcia-Valenzuela E., Salierno A., Walsh J., and Sharma S.C. Chronic ocular hypertension following episcleral venous occlusion in rats. Exp. Eye Res. 61 (1995) 379-382
44. Serle J.B. A comparison of safety and efficacy of twice daily brimonidine 0.2% versus betaxolol in subjects with elevated intraocular pressure. The Brimonidine Study Group III. Surv. Ophthalmol. 41 (1996) S39-S47
45. The AGIS Investigators. The advanced glaucoma intervention study (AGIS): the relationship between control of intraocular pressure and visual field deterioration. Am. J. Ophthalmol. 130 (2000) 429-440
46. Urcola J.H., Hernández M., and Vecino E. Three experimental glaucoma models in rats: comparison of the effects of intraocular pressure elevation on retinal ganglion cell size and death. Exp. Eye Res. 83 (2006) 429-437
47. Vecino E., Garcia-Grespo D., Garcia M., Martinez-Millan L., Sharma S.C., and Carrascal E. Rat retinal ganglion cells co-express brain derived neurotrophic factor (BDNF) and its receptor TrkB. Vision Res. 42 (2002) 151-157
48. Vorwerk C.K., Lipton S.A., Zurakowski D., Hyman B.T., Sabel B.A., and Dreyer E.B. Chronic low-dose glutamate is toxic to retinal ganglion cells. Toxicity blocked by mementine. Invest. Ophthalmol. Vis. Sci. 37 (1996) 1618-1624
49. Wang R.F., Serle J.B., Gagliuso D.J., and Podos S.M. Comparison of hypotensive effect of brimonidine, dorzolamide, latanoprost or artificial tears added to timolol in glaucomatous monkey eyes. J. Glaucoma 9 (2000) 458-462
50. Wheeler L.A., and Woldemussie E. Alpha-2 adrenergic receptor agonists are neuroprotective in experimental models of glaucoma. Eur. J. Ophthalmol. 11 (2001) S30-S35
51. Wheeler L.A., Gil D.W., and WoldeMussie E. Role of alpha-2 adrenergic receptors in neuroprotection and glaucoma. Surv. Ophthalmol. 45 (2001) S290-S294
52. Wheeler L.A., Tatton N.A., and Elstner M. Alpha-2 adrenergic receptor activation by brimonidine reduces neuronal apoptosis through Akt (protein Kinase B) dependent new synthesis of BCL-2. Invest. Ophthalmol. Vis. Sci. 42 (2001) S411
53. Wheeler L.A., WoldeMussie E., and Lai R. Role of alpha-2 agonist in neuroprotection. Surv. Ophthalmol. 48 (2003) S47-S51
54. Weinreb R.N., Lindsey J.D., Marchenko G., Marchenko N., Angert M., and Strongin A. Prostaglandin FP agonist alter metalloproteinase gene expression in sclera. Invest. Ophthalmol. Vis. Sci. 45 (2004) 4368-4377
55. WoldeMussie E., Ruiz G., Wijono M., and Wheeler L.A. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest. Ophthalmol. Vis. Sci. 42 (2001) 2849-2855
56. Yoles E., Wheeler L.A., and Schwartz M. Alpha2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration. Invest. Ophthalmol. Vis. Sci. 40 (1999) 65-73